The Novel Nuclear Factor-κB Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine

Saman Hewamana, Thet Thet Lin, Chris Jenkins, Alan K Burnett, Craig T Jordan, Chris Fegan, Paul Brennan, Clare Rowntree, Chris Pepper

Research output: Contribution to journalArticle

45 Citations (Scopus)

Fingerprint Dive into the research topics of 'The Novel Nuclear Factor-κB Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine'. Together they form a unique fingerprint.

Medicine & Life Sciences